- Home
- CCCC vs GRX Comparison
CCCC vs GRX Comparison
Compare CCCC & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- GRX
- Stock Information
- Founded
- CCCC 2015
- GRX 2007
- Country
- CCCC United States
- GRX United States
- Employees
- CCCC N/A
- GRX N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- CCCC Health Care
- GRX Finance
- Exchange
- CCCC Nasdaq
- GRX Nasdaq
- Market Cap
- CCCC 175.1M
- GRX 145.5M
- IPO Year
- CCCC 2020
- GRX N/A
- Fundamental
- Price
- CCCC $2.23
- GRX $8.98
- Analyst Decision
- CCCC Strong Buy
- GRX
- Analyst Count
- CCCC 4
- GRX 0
- Target Price
- CCCC $8.50
- GRX N/A
- AVG Volume (30 Days)
- CCCC 1.8M
- GRX 39.7K
- Earning Date
- CCCC 10-30-2025
- GRX 01-01-0001
- Dividend Yield
- CCCC N/A
- GRX 5.98%
- EPS Growth
- CCCC N/A
- GRX N/A
- EPS
- CCCC N/A
- GRX 0.26
- Revenue
- CCCC $34,240,000.00
- GRX N/A
- Revenue This Year
- CCCC N/A
- GRX N/A
- Revenue Next Year
- CCCC N/A
- GRX N/A
- P/E Ratio
- CCCC N/A
- GRX $38.50
- Revenue Growth
- CCCC 16.55
- GRX N/A
- 52 Week Low
- CCCC $1.09
- GRX $7.73
- 52 Week High
- CCCC $7.14
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- CCCC 38.70
- GRX 32.49
- Support Level
- CCCC $2.13
- GRX $8.96
- Resistance Level
- CCCC $3.43
- GRX $9.26
- Average True Range (ATR)
- CCCC 0.30
- GRX 0.09
- MACD
- CCCC -0.12
- GRX -0.04
- Stochastic Oscillator
- CCCC 6.58
- GRX 3.64
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.